Truist raised the firm’s price target on Medtronic (MDT) to $103 from $96 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in MedTech. The firm expects “healthy” Q3 revenue and earnings across its coverage but also braces for “stock volatility”, with new money feeling notably absent from the space, the analyst tells investors in a research note. Similar to Q2, specialist and fund positioning could be poised to drive excessive reactions on anything counter to crowded positioning, Truist states, adding that it is more inclined to be positive on “cleaner” names where there is less perceived controversy heading into the quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $111 from $103 at RBC Capital
- Medtronic’s Altaviva Device: A Promising Market Expansion with Competitive Advantages
- Medtronic’s Hold Rating: Balancing Promising Innovations with Market Challenges
- Medtronic’s Strategic Positioning and Innovative Solutions Drive Buy Rating
- Medtronic price target raised to $105 from $90 at Stifel